HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

L'Oreal opens factory in Russia

This article was originally published in The Rose Sheet

Executive Summary

French cosmetics giant announces Sept. 23 the opening of its first factory in Russia. The 10,000-square-meter facility is expected to reach an output of 120 million units per year and has the option to expand production two-fold "as demand continues to evolve." The plant - L'Oreal's 38 manufacturing facility - is located south of Moscow and will manufacture shampoo, hair conditioner and hair dye for firm's L'Oreal Paris and Garnier brands for distribution in Russia, Ukraine and other Central European countries. L'Oreal sales in Russia have tripled since 2004, reaching €563 mil. ($757 mil.) in 2009. The factory's opening "reflects L'Oreal's commitment to locate industrial operations teams as close as possible to key markets to seize opportunities more effectively and to be more responsive, bringing success to product launches in Russia," Operations Managing Director Jean-Philippe Blanpain says

You may also be interested in...



Biocon-Mylan's Plans For Broader US Fulphila Access, Glargine On Track

Biocon-Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the initial uptake for their trastuzumab biosimilar ahead of more upcoming competition. A mid-2020 US launch for partnered insulin glargine is also on course.

JT Gains World-First Topical JAK Inhibitor Approval

Latest new drug approvals in Japan include the first anywhere for a topical JAK inhibitor and also a marketing clearance for a new contender in the large prostate cancer space.

QUOTED. 27 January 2020. John McKay.

Consultant John McKay encourages device makers to ask questions of the US FDA’s inspection team during a facility audit. Check out his advice here.

UsernamePublicRestriction

Register

RS017214

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel